Graphical Abstract
CNS & Neurological Disorders - Drug Targets
Title:Commentary: Let the Time Fly: Dopamine is the Arbiter
Volume: 17 Issue: 1
Author(s): Xiaodong Liu, Changzheng Zhang, Oscar Arias-Carrion* Ti-Fei Yuan*
Affiliation:
- Trastornos del Movimiento y Sueno, Hospital General Dr. Manuel Gea Gonzalez, Ciudad de Mexico,Mexico
- Shanghai Key Laboratory of Psychotic Disorders, Shanghai Mental Health Center, Shanghai Jiao Tong University School of Medicine, Shanghai,China
Export Options
About this article
Cite this article as:
Liu Xiaodong, Zhang Changzheng, Arias-Carrion Oscar *, Yuan Ti-Fei *, Commentary: Let the Time Fly: Dopamine is the Arbiter, CNS & Neurological Disorders - Drug Targets 2018; 17 (1) . https://dx.doi.org/10.2174/1871527316999170505110106
DOI https://dx.doi.org/10.2174/1871527316999170505110106 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Role of Vitamin D in Autism Spectrum Disorder
Current Pharmaceutical Design Signalling Pathways Activated by Ultraviolet Radiation: Role in Ocular and Cutaneous Health
Current Pharmaceutical Design New Missions for an Old Agent: Granulocyte-Colony Stimulating Factor in the Treatment of Stroke Patients
Current Medicinal Chemistry Modulation of Endoplasmic Reticulum Stress: An Opportunity to Prevent Neurodegeneration?
CNS & Neurological Disorders - Drug Targets Association between Serum Lipids and Antipsychotic Response in Schizophrenia
Current Neuropharmacology The Impact of Comorbid Diabetes Type 2 on Quality of Life in Cancer Patients Undergoing Chemotherapy
Endocrine, Metabolic & Immune Disorders - Drug Targets Amyloid Beta 1-42 Inhibits Entorhinal Cortex Activity in the Beta-Gamma Range: Role of GSK-3
Current Alzheimer Research Advances in Nanomedicine Towards Clinical Application in Oncology and Immunology
Current Pharmaceutical Biotechnology Mechanistic Insights into Mode of Action of a Potent Natural Antagonist of Orexin Receptor-1 by Means of High Throughput Screening and Molecular Dynamics Simulations
Combinatorial Chemistry & High Throughput Screening Screening and Partial Purification of Cholinesterase Inhibitor from Microalgae
Current Enzyme Inhibition Effect of Magnetic Resonance Applications on Dental Amalgam Phase Changes
Current Medical Imaging Social Determinants of Childhood Obesity: Beyond Individual Choices
Current Pediatric Reviews Tumour-Derived Glutamate: Linking Aberrant Cancer Cell Metabolism to Peripheral Sensory Pain Pathways
Current Neuropharmacology Pleiotropic Actions of PPARg Activators Thiazolidinediones in Cardiovascular Diseases
Current Pharmaceutical Design Pharmacological Treatment of Hypertension in Pregnancy
Current Pharmaceutical Design The Plasma Membrane: A Target and Hurdle for the Development of Anti- A? Drugs?
Current Drug Targets - CNS & Neurological Disorders Phytochemicals as Adjunctive with Conventional Anticancer Therapies
Current Pharmaceutical Design Cancer Drug Development with the Help of Radiopharmaceuticals: Academic Experience
Current Pharmaceutical Design Attenuation of ERK/RSK2-Driven NFκB Gene Expression and Cancer Cell Proliferation by Kurarinone, a Lavandulyl Flavanone Isolated from Sophora flavescens Ait. Roots
Endocrine, Metabolic & Immune Disorders - Drug Targets Presynaptic NR2B-Containing NMDA Autoreceptors Mediate Glutamatergic Synaptic Transmission in the Rat Visual Cortex
Current Neurovascular Research